CN1054515C - Medicine for prevention and cure of hepatitis B - Google Patents
Medicine for prevention and cure of hepatitis B Download PDFInfo
- Publication number
- CN1054515C CN1054515C CN93104180A CN93104180A CN1054515C CN 1054515 C CN1054515 C CN 1054515C CN 93104180 A CN93104180 A CN 93104180A CN 93104180 A CN93104180 A CN 93104180A CN 1054515 C CN1054515 C CN 1054515C
- Authority
- CN
- China
- Prior art keywords
- radix
- root
- weight
- drug
- percentage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a traditional Chinese medicinal drug for preventing and treating hepatitis B, which is prepared from 9 kinds of traditional Chinese medicines comprising milkvetch root, heterophylly falsesatarwort root, wolfberry fruit, bupleurum root, white peony root, red sage root, giant knotweed rhizome, oldenlandia, prepared rhubarb, etc. The drug can be prepared into Chinese patent medicines, such as water diffusion pills, concentrated pills, capsules, granules, paste agents, etc. by utilizing the formula and a conventional method for processing traditional Chinese medicines. Clinical verification shows that a negative transform rate of HBSAg and HBEAg is more than 60%, a total effective rate is 90%, a rebound rate is low, and the inhibition of hepatitis B viruses is stable and lasting after patients take the drug. Meanwhile, the drug also has good curative effects on fatty liver.
Description
The present invention relates to a kind of Chinese medicine medicine for the treatment of hepatitis B.
As everyone knows, acute and chronic hepatitis B is commonly encountered diseases and a frequently-occurring disease clinically, and the generation of this disease and infection are seriously endangering the healthy of people.The countries in the world medical worker, all be devoted to study the medicine of seeking the treatment hepatitis B, up to the present, still there is not comparatively ideal medicine, as fall enzyme and fall the two enzymes of the turbid medicine Fructus Schisandrae Chinensis preparation of zinc and biphenyl, to fall enzyme fast although use it clinically, and amplitude is big, but the knock-on rate is up to more than 60%, and correlation is turbid, jaundice and Australia antigen are turned out cloudy does not have obviously effect; Example: hepatic glucuronolatone, Aicamin, coenzyme A, inosine etc. and anti-hepatitis virus medicament interferon and arabinose arteries and veins glycosides etc., can make part patient HBSAg, HBeAg turns out cloudy or titre descends, and e antibody and archaeal dna polymerase lowering of concentration appear, in case but drug withdrawal, easily knock-on is multiple rises, and is unabiding to the inhibition of hepatitis B virus; The specificity of immunomodulator is exempted from the u immvore RNA for another example, has to transmit HBSAg immunologic information improved effect liver function e antigen and surface antigen is turned out cloudy or titre descends, and produces little effect, and transfer factor can make doing well,improving, but to HBSAg and turn out cloudy and not obvious.
In view of said medicine in treatment hepatitis B existing deficiency, purpose of the present invention is to develop a kind of HBSAg and the HBeAg negative conversion rate is higher, the knock-on rate is low, and hepatitis B virus is suppressed to stablize persistent Chinese medicine medicine.
Chinese medicine medicine of the present invention is made up of nine flavor Chinese medicine medicines such as the Radix Astragali, Radix Pseudostellariae, Fructus Lycii, Radix Bupleuri, the Radix Paeoniae Alba, Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati, Herba Hedyotidis Diffusae, Radix Et Rhizoma Rhei.
Ingredient of the present invention is formed (percentage by weight) scope: Radix Astragali 10-20%, Radix Pseudostellariae 10-20%, Fructus Lycii 6-14%, Radix Bupleuri 6-14%, Radix Paeoniae Alba 5-12%, Rhizoma Polygoni Cuspidati 5-12%, Herba Hedyotidis Diffusae 10-20%, Radix Salviae Miltiorrhizae 8-16%, Radix Et Rhizoma Rhei 3-8%.Each component summation is 100%.
Optimum ingredient is formed (percentage by weight): Radix Astragali 13-17%, Radix Pseudostellariae 13-17%, Fructus Lycii 8.5-11.5%, Radix Bupleuri 8.5-11.5%, Radix Paeoniae Alba 7-10%, Radix Salviae Miltiorrhizae 10-14%, Rhizoma Polygoni Cuspidati 7-10%, Herba Hedyotidis Diffusae 13-17%, Radix Et Rhizoma Rhei 4-6%.Each component summation is 100%.
Utilize the prescription of drug component of the present invention, adopt common Chinese medicine processing method, can be made into Chinese patent medicines such as water pill, concentrated pill, capsule, electuary and paste nourishing agent.
Embodiment: carrying out Chinese medicine of the present invention when producing, its compound method is as follows:
(1) water pill agent.With nine flavor Chinese medicines, it is qualified to remove foreign body, impurity, the process of preparing Chinese medicine, weighs by recipe ingredient and assorts, and pulverizes then, crosses 80-100 mesh sieve and even; Get an amount of refined honey and be dissolved in cold boiled water, general is spherical piller; Dry or cold drying, can pack stand-by.
(2) concentrated pill.Nine flavor Chinese medicines are cleaned, and it is qualified to concoct, and weighs by recipe ingredient and assorts; Pulverized 100-120 order dusting cover then; Carry through boiling, the leaching medicinal liquid is condensed into ball; Cold drying, it is stand-by to bottle.
(3) capsule.With nine flavor Chinese medicines, remove foreign body, it is qualified that impurity is concocted; Weigh by recipe ingredient and to assort; Pulverize then, cross the 80-100 mesh sieve, and with even; At last medicated powder equivalent is incapsulated.
(4) electuary.With nine flavor Chinese medicines, remove foreign body, impurity; Weigh by recipe ingredient and to assort; The material of getting it filled decocts with water twice, boils two hours at every turn; The squeezing extracting juice; Collecting decoction leaves standstill filtration; Filtering decocting liquid is condensed into cream (proportion is 1.22-1.23); Add cane sugar powder and dextrin mixing, make granule, carry out low temperature (must not above 60 ℃) drying, pack stand-by then
(5) paste nourishing agent.With nine flavor Chinese medicines, remove foreign body, impurity, to weigh by recipe ingredient and assort, the material of getting it filled decocts with water twice, boils two hours at every turn; The squeezing extracting juice filters collecting decoction then; Decocting liquid is condensed into clear paste; Other gets refining Mel, and to add water an amount of, and heating for dissolving, merges with clear paste and even, and the ratio of the cream 1.35-1.38 that weighs is got final product, and it is stand-by to bottle at last.
Below be method and effect with Chinese medicine treatment hepatitis B of the present invention.
Use Chinese Traditional Medicines of the present invention surplus clinical 1700 routine patient take statistics Show: HBSAg, HBeAg negative conversion rate are greater than 60%, and total effective rate is 90%, and the knock-on rate is 10.8%, hepatitis B is suppressed stable lasting, drug withdrawal 6-12 month is unchanged.
Claims (2)
1, a kind of Chinese medicine medicine for the treatment of hepatitis B, it is characterized in that: be that following row raw materials by weight percent is made: Radix Astragali 10-20%, Radix Pseudostellariae 10-20%, Fructus Lycii 6-14%, Radix Bupleuri 6-14%, Radix Paeoniae Alba 5-12%, Radix Salviae Miltiorrhizae 8-16%, Rhizoma Polygoni Cuspidati 5-12%, Herba Hedyotidis Diffusae 10-20%, Radix Et Rhizoma Rhei 3-8%.
2, a kind of Chinese medicine medicine according to claim 1, it is characterized in that: the percentage by weight of the used Radix Astragali is 13-17%, the percentage by weight of Radix Pseudostellariae is 13-17%, the percentage by weight of Fructus Lycii is 8.5-11.5%, and the percentage by weight of Radix Bupleuri is 8.5-11.5%, and the percentage by weight of the Radix Paeoniae Alba is 7-10%, the percentage by weight of Radix Salviae Miltiorrhizae is 10-14%, the percentage by weight of Rhizoma Polygoni Cuspidati is 7-10%, and the percentage by weight of Herba Hedyotidis Diffusae is 13-17%, and the percentage by weight of Radix Et Rhizoma Rhei is 4-6%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93104180A CN1054515C (en) | 1993-04-11 | 1993-04-11 | Medicine for prevention and cure of hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93104180A CN1054515C (en) | 1993-04-11 | 1993-04-11 | Medicine for prevention and cure of hepatitis B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1083712A CN1083712A (en) | 1994-03-16 |
| CN1054515C true CN1054515C (en) | 2000-07-19 |
Family
ID=4985052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93104180A Expired - Fee Related CN1054515C (en) | 1993-04-11 | 1993-04-11 | Medicine for prevention and cure of hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1054515C (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1052886C (en) * | 1994-05-31 | 2000-05-31 | 胡建华 | Chinese drug powder for curing hepatitis B and its preparing method |
| CN1066628C (en) * | 1996-02-15 | 2001-06-06 | 邵阳县中医院 | Medicine for chronic hepatitis B and its preparation |
| CN1059811C (en) * | 1997-03-07 | 2000-12-27 | 马俊龙 | Complete set of Chinese medicine preparations for curing hepatitis B |
| CN1067900C (en) * | 1998-11-17 | 2001-07-04 | 董国良 | Medicine bolus for hepatitis B and its preparation |
| CN100386099C (en) * | 2005-04-05 | 2008-05-07 | 魏伟 | Peony astragalus polyglucoside composition for treating liver disease and its preparation method |
| CN1305516C (en) * | 2005-09-27 | 2007-03-21 | 韩云超 | Chinese medicine for treating chronic hepatitis B |
| CN105106777A (en) * | 2015-09-16 | 2015-12-02 | 宋克垣 | Drug for treating hepatitis B and preparation method thereof |
| CN108578636A (en) * | 2018-06-08 | 2018-09-28 | 邓波 | A kind of pharmaceutical preparation and preparation method thereof for treating hepatopathy |
-
1993
- 1993-04-11 CN CN93104180A patent/CN1054515C/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 山西医药杂志1984,13(6) 1984.6.1 张荣显等，用活血化淤法为主治疗小儿乙型肝炎214例临床观察 * |
| 山西医药杂志1984,13(6) 1984.6.1 张荣显等，用活血化淤法为主治疗小儿乙型肝炎214例临床观察;陕西中医1985,6(8) 1985.8.1 赖祥林等，抗乙肝冲剂治疗乙型肝炎56例疗效观察 * |
| 陕西中医1985,6(8) 1985.8.1 赖祥林等，抗乙肝冲剂治疗乙型肝炎56例疗效观察 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1083712A (en) | 1994-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1044974C (en) | Anti- hepatitis B preparation | |
| AU2002213403A1 (en) | Novel medicinal herbal composition for treating liver diseases and HIV | |
| CN102688303A (en) | Health liver-protecting tea and making method thereof | |
| CN102335335A (en) | Traditional Chinese medicine preparation with effects of health care and physical fatigue alleviation | |
| KR20230057438A (en) | Compositions of ginsenosides Rg3 and ginsenosides Rg5 and pharmaceutical uses thereof, including antitumor effects | |
| CN104644915A (en) | Pharmaceutical composition for treating alcoholic liver diseases as well as preparation method and application of pharmaceutical composition | |
| CN107206042B (en) | The drug or health products of prevention or treatment lesions of liver and kidney relevant disease and its application | |
| CN1054515C (en) | Medicine for prevention and cure of hepatitis B | |
| CN102188634B (en) | Chinese medicine composition for treating hyperuricemia | |
| CN101011562B (en) | Novel formulation of shenqiwendan decoction and production method thereof | |
| CN1145240A (en) | Medicinal compsn. for prevention of Aids virus and cancer | |
| CN108042766A (en) | A kind of Bushen Tongluo supports brain cream and preparation method thereof | |
| CN102949481A (en) | Health care tea for reducing blood pressure and blood lipid | |
| CN102008598B (en) | Blood fat-lowering and liver-protecting composite as well as preparation prepared thereby and preparation method of preparation | |
| CN101390970B (en) | Traditional Chinese medicine for treating hepatitis B and preparation method thereof | |
| CN104225472B (en) | A kind of Chinese medicine preparation and preparation method and purposes for treating Oral mucosal lesion | |
| CN105250427A (en) | Pharmaceutical composition for treating heart diseases | |
| CN103933280A (en) | Traditional Chinese medicine composition for treating PCI (percutanecus coronary intervention) postoperative angina of phlegm-obstructing heart vessel type coronary heart disease and application thereof | |
| CN100453108C (en) | Chinese medicine composition with nourishing health function and its preparing method | |
| CN112914009A (en) | Health-care solid beverage for yang-deficiency constitution and preparation method thereof | |
| CN111000962B (en) | Chinese patent medicine for treating functional dyspepsia of spleen deficiency and damp stagnation syndrome and preparation method thereof | |
| CN102631492A (en) | Chinese medicinal composition for improving immunity and resisting fatigue | |
| CN1056759C (en) | Traditional Chinese medicine preparation for prevention and treatment of hepatitis B | |
| CN105641168A (en) | Medicine for treating viral hepatitis B and viral hepatitis C and preparation method of medicine | |
| CN1061885C (en) | Specific infusion for hepatitis B and producing process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |